Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase I/II Study of Safety & Efficacy of Perifosine & Bortezomib With or Without Dexamethasone for Multiple Myeloma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 218 NCT00401011


2.		Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 217 NCT00391560


3.		A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				13 and over				Pharmaceutical / Industry				Perifosine 214 NCT00401388


4.		Clinical and Molecular-Metabolic Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 222 NCT00400920


5.		A Ph II Trial of Perifosine Following TKI-Failure in Patients With Renal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosne 228 NCT00448721


6.		Ph II Study of Perifosine Plus Gleevec for Patients With GIST

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 210 NCT00455559


7.		Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 231 NCT00498966

Last Modified: 6/4/2007 First Published: 3/3/2006


8.		Phase I Study of UCN-01 in Combination With Perifosine in Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or High Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MSGCC-0507 MSGCC-H-27229-0507, NCI-7311, 7311, NCT00301938


9.		Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 124 NCT00398814


10.		Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 127 NCT00415064

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute